πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11479613

Methods for treating cancer or modulating T cells or NK cells in a subject by administerin

AUTOLUS LIMITED Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11479614

Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by

AUTOLUS LIMITED Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11473060

Compositions and methods for differentiating stem cells into NK cells

CRISPR THERAPEUTICS AG Β· Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11471491

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG Β· Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11472884

Humanized BCMA antibody and BCMA-CAR-T cells

Caribou Biosciences, Inc. Β· Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11464807

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11458212

Molecular imaging of cancer cells in vivo

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11458171

Engineering stem cells for cancer therapy

China Medical University Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11459560

Methods and compositions for reprogramming cells

The Regents of the University of Colorado Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11459372

Gene-edited natural killer cells

CRISPR THERAPEUTICS AG Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11453861

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

Precision BioSciences, Inc. Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11446357

Method for treating disease using FOXP3+CD4+ T cells

Kyverna Therapeutics, Inc. Β· Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11446302

Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutat

The Board of Regents of the University of Texas System Β· Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11441184

Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11433103

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11434505

Universal donor cells

CRISPR THERAPEUTICS AG Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11419883

Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes

The Regents of the University of California Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11421010

T cells expressing membrane-anchored IL-12 for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11400118

Methods for production of platelets from pluripotent stem cells and compositions thereof

Astellas Institute for Regenerative Medicine Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11401510

Generation of airway basal stem cells from human pluripotent stem cells

The Board of Regents of the University of Texas System Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11400116

Systems and methods for targeting cancer cells

The Regents of the University of California Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11390921

Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

Adaptive Biotechnologies Corporation Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11389481

Allogeneic cell therapy of B cell malignancies using genetically engineered T cells target

CRISPR THERAPEUTICS AG Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11389485

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted